Giulia D’Amore

Feb 19, 2024 | journals.sagepub.com | Maria A Rocca |Paola Valsasina |Nicolò Tedone |Giulia D’Amore

IntroductionMultiple sclerosis (MS) is characterized by complex pathological substrates, resulting in non-uniform clinical manifestations and variable disease progression.1 Therefore, determining biomarkers associated with an unfavorable disease course is of paramount importance to optimize patients’ management. Magnetic resonance imaging (MRI)–derived measures are good candidates for identifying mechanisms associated with disability progression and cognitive deterioration.